Medical management of intermittent claudication.
The symptoms of intermittent claudication (IC) lead sufferers to seek medical attention, potentially leading to substantial workup and invasive testing. However, only a minority of people with IC develop limb-threatening ischemia or symptoms of significant lifestyle-limiting claudication. Patients with IC have a substantial risk of concomitant cardiovascular and cerebrovascular disease. Assessment of co-morbidities and control of risk factors reduce the cardiovascular risk of these patients. A multitude of drugs have been developed and tested in numerous trials for the symptoms of IC. Although no drug alone offers a "cure" to IC, some are used as adjuvant therapy to reduce claudication symptoms.
Casey
Kevin
K
Department of Vascular Surgery, Ochsner Clinic Foundation, New Orleans, LA 70121, USA.
Tonnessen
Britt H
BH
Sternbergh
W Charles
WC
Money
Samuel R
SR
D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000150:complications / Q000517:prevention & control*; D002561:Cerebrovascular Disorders / Q000150:complications / Q000517:prevention & control*; D015444:Exercise; D006801:Humans; D007383:Intermittent Claudication / Q000150:complications* / Q000188:drug therapy*; D012307:Risk Factors
D002317:Cardiovascular Agents